Sonrotoclax is an antineoplastic.
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines[1].
Sonrotoclax (compound 1; 5-50 mg/kg; p.o.; daily, for 42 d; female NCG mice with acute lymphoblastic leukemia (ALL) xenografts) has antineoplastic activity and inhibits tumor growth[1].
| Animal Model: | Female NCG mice with acute lymphoblastic leukemia (ALL) xenografts[1] |
| Dosage: | 5, 15, 50 mg/kg |
| Administration: | oral administration; daily, for 42 days |
| Result: | Inhibited tumor growth in a dose-dependent manner. |
[1] Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1.